🚀 VC round data is live in beta, check it out!
Cue Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cue Biopharma and similar public comparables like Boundless Bio, Evaxion, Barinthus Biotherapeutics, Mendus and more.
Cue Biopharma Overview
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Founded
2014
HQ
Employees
41
Website
Sectors
Financials (LTM)
EV
$14M
Cue Biopharma Financials
Cue Biopharma reported last 12-month revenue of $21M.
In the same LTM period, Cue Biopharma generated had net loss of ($27M).
Revenue (LTM)
Cue Biopharma P&L
In the most recent fiscal year, Cue Biopharma reported revenue of $27M and EBITDA of ($22M).
Cue Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21M | XXX | $27M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (81%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (97%) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | (127%) | XXX | (97%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cue Biopharma Stock Performance
Cue Biopharma has current market cap of $26M, and enterprise value of $14M.
Market Cap Evolution
Cue Biopharma's stock price is $0.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $26M | 0.0% | XXX | XXX | XXX | $-0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCue Biopharma Valuation Multiples
Cue Biopharma trades at 0.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.
EV / Revenue (LTM)
Cue Biopharma Financial Valuation Multiples
As of April 1, 2026, Cue Biopharma has market cap of $26M and EV of $14M.
Equity research analysts estimate Cue Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cue Biopharma has a P/E ratio of (1.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.5x) | XXX | XXX | XXX |
| P/E | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cue Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cue Biopharma Margins & Growth Rates
Cue Biopharma's revenue in the last 12 month declined by (95%).
Cue Biopharma's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.3M for the same period.
Cue Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (95%) | XXX | (96%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (81%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (41%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 59% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 137% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 197% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cue Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Boundless Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Evaxion | XXX | XXX | XXX | XXX | XXX | XXX |
| Barinthus Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mendus | XXX | XXX | XXX | XXX | XXX | XXX |
| FibroBiologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cue Biopharma M&A Activity
Cue Biopharma acquired XXX companies to date.
Last acquisition by Cue Biopharma was on XXXXXXXX, XXXXX. Cue Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cue Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCue Biopharma Investment Activity
Cue Biopharma invested in XXX companies to date.
Cue Biopharma made its latest investment on XXXXXXXX, XXXXX. Cue Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cue Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cue Biopharma
| When was Cue Biopharma founded? | Cue Biopharma was founded in 2014. |
| Where is Cue Biopharma headquartered? | Cue Biopharma is headquartered in United States. |
| How many employees does Cue Biopharma have? | As of today, Cue Biopharma has over 41 employees. |
| Who is the CEO of Cue Biopharma? | Cue Biopharma's CEO is Usman Azam. |
| Is Cue Biopharma publicly listed? | Yes, Cue Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Cue Biopharma? | Cue Biopharma trades under CUE ticker. |
| When did Cue Biopharma go public? | Cue Biopharma went public in 2018. |
| Who are competitors of Cue Biopharma? | Cue Biopharma main competitors are Boundless Bio, Evaxion, Barinthus Biotherapeutics, Mendus. |
| What is the current market cap of Cue Biopharma? | Cue Biopharma's current market cap is $26M. |
| What is the current revenue of Cue Biopharma? | Cue Biopharma's last 12 months revenue is $21M. |
| What is the current revenue growth of Cue Biopharma? | Cue Biopharma revenue growth (NTM/LTM) is (95%). |
| What is the current EV/Revenue multiple of Cue Biopharma? | Current revenue multiple of Cue Biopharma is 0.6x. |
| Is Cue Biopharma profitable? | No, Cue Biopharma is not profitable. |
| What is the current net income of Cue Biopharma? | Cue Biopharma's last 12 months net income is ($27M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.